The use of proteolysis-resistant GLP-1 analogs to treat patients with T2DM and MS; the development of the proteolysis-resistant leptin and melanocortin analogs by the chemical modification, the amino acid substitutions and the synthesis of truncated analogs. This evidence concerns the gene GCG and type 2 diabetes mellitus.